Elevated serum levels of Si 00 and survival in metastatic malignant melanoma
1997

Serum S100 Levels and Survival in Melanoma

Sample size: 99 publication Evidence: moderate

Author Information

Author(s): J Buerl, M Probst, A Franzke, S Duensing, J Haindl, M Volkenandt, F Wittke, R Hoffmann, A Ganser, J Atzpodien

Primary Institution: Medizinische Hochschule Hannover

Hypothesis

Elevated serum levels of S100 are correlated with poor outcomes in patients with metastatic malignant melanoma.

Conclusion

Elevated serum levels of S100 are associated with poorer survival in patients with metastatic malignant melanoma, but do not provide additional prognostic information beyond established clinical parameters.

Supporting Evidence

  • Elevated serum levels of S100 were detected in 22 patients and were associated with a median survival of 6 months.
  • Patients with serum S100 below 3 µg/l achieved a median survival of 13 months.
  • LDH and liver metastases were found to be significant independent prognostic factors.

Takeaway

This study found that higher levels of a protein called S100 in the blood can mean that patients with a type of skin cancer called melanoma might not live as long.

Methodology

The study used univariate and multivariate Cox proportional-hazards models to analyze serum S100 levels and clinical factors in relation to overall survival.

Limitations

S100 lost its statistical significance when combined with other prognostic markers, indicating it may not be independently useful.

Participant Demographics

Patients with histologically confirmed metastatic malignant melanoma, with a performance status of 70% or higher.

Statistical Information

P-Value

<0.001

Confidence Interval

95% CI 0.43-0.70 for serum LDH; 95% CI 0.59-0.98 for liver metastases

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication